Advertisement

Topics

Novo Nordisk, Inc. Company Profile

06:42 EDT 2nd May 2016 | BioPortfolio

Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success. Headquartered in Denmark, Novo Nordisk employs more than 29,650 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchange in Copenhagen and its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk-us.com.


News Articles [475 Associated News Articles listed on BioPortfolio]

NASDAQ OMX Nordic: Derivatives: Anticipated adjustment due to additional dividend in Novo Nordisk (26/16)

The following information is based on a press release from Novo Nordisk A/S (Novo Nordisk) published on February 3, 2016 and may be subject to change. The board of Novo Nordisk has proposed an addi...

NASDAQ OMX Nordic: Derivatives: Correction - Anticipated adjustment due to additional dividend in Novo Nordisk (29/16)

Please disregard from exchange notice (26/16) regarding additional dividend in Novo Nordisk A/S (Novo Nordisk) published on February 26, 2016. The board of Novo Nordisk proposed, in a press release...

BRIEF-Novo Nordisk says Kolding to not seek re-election for board

* Novo Nordisk A/S: proposed changes in composition of the board of directors of Novo Nordisk

Novo Nordisk A/S: Novo Nordisk A/S - Trading in Novo Nordisk shares by board members, executives and associated persons on 3 November 2015

Bagsvaerd, Denmark, 4 November 2015 In accordance with Section 28a of the Danish Securities Trading Act, the company's board members and executives have given Novo Nordisk power of attorney on the...

Novo Nordisk A/S: Novo Nordisk A/S - Trading in Novo Nordisk shares by board members, executives and associated persons on 29 October 2015

Bagsvaerd, Denmark, 30 October 2015 In accordance with Section 28a of the Danish Securities Trading Act, the company's board members and executives have given Novo Nordisk power of attorney on the...

Articles of Association of Novo Nordisk A/S

Articles of Association of Novo Nordisk A/S Articles of Association of Novo Nordisk A/SThis announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solut...

Novo Nordisk A/S: Articles of Association

Articles of Association of Novo Nordisk A/S Articles of Association of Novo Nordisk A/SThis announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solut...

CEO of Novo Nordisk's biggest shareholder steps down

COPENHAGEN, Feb 12 (Reuters) - Novo A/S, the parent company behind the world's largest insulin maker Novo Nordisk said on Friday Chief Executive Eivind Kolding will step down at the end of the month. ...

Drugs and Medications [33 Associated Drugs and Medications listed on BioPortfolio]

Novolin [Novo Nordisk]

Novolin 70/30, 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin)

Novolin [Novo Nordisk]

NOVOLIN N Human Insulin Isophane Suspension (recombinant DNA origin) 100 units/mL

Novolin [Novo Nordisk]

Novolin 70/30, 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin)

Novolin [Physicians Total Care, Inc.]

Novolin 70/30, 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin)

Novolin [Novo Nordisk]

R HUMAN Novolin R Regular, Human Insulin Injection (recombinant DNA origin) USP 100 units/mL

PubMed Articles [290 Associated PubMed Articles listed on BioPortfolio]

Liraglutide for Type 2 diabetes and obesity: a 2015 update.

Subcutaneous liraglutide (Victoza(®), Novo Nordisk) was approved for the treatment of Type 2 diabetes mellitus (T2DM) in Europe in 2009 and in the USA in 2010. In December 2014, liraglutide 3.0 mg wa...

Dosing Accuracy of Two Disposable Insulin Pens According to New ISO 11608-1: 2012 Requirements.

The aim was to compare 2 disposable insulin pens, FlexTouch® (Novo Nordisk, insulin aspart) and SoloSTAR® (Sanofi, insulin glulisine), according to new ISO 11608-1:2012 requirements for dosing accur...

De novo arteriovenous malformation in a patient with hereditary hemorrhagic telangiectasia.

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant systemic disorder characterized by the enlargement of capillaries, recurrent nosebleeds, and multiple arteriovenous malformations (...

Recent developments in computational methods for de novo peptide sequencing from tandem mass spectrometry (MS/MS).

Tandem mass spectrometry (MS/MS) has emerged as a major technology for peptide sequencing. Typically, there are three kinds of methods for the peptide sequencing: database searching, peptide tagging, ...

Rapid centriole assembly in naegleria reveals conserved roles for both de novo and mentored assembly.

Centrioles are eukaryotic organelles whose number and position are critical for cilia formation and mitosis. Many cell types assemble new centrioles next to existing ones ('templated' or mentored asse...

Clinical Trials [258 Associated Clinical Trials listed on BioPortfolio]

Evaluation of the Effects of Different Interventions on Glycemic Control in Newly-Diagnosed Type 2 Diabetic Patients

The purpose of this study is to investigate and evaluate the effects of different interventions (1.continuous subcutaneous insulin infusion,2.multiple daily injections, 3.anti-hyperglycemi...

To Study Generic Estradiol 10 mcg Vaginal Tablets in the Treatment of Vulvar and Vaginal Atrophy in Post Menopausal Women.

This is a Randomized, Parallel-Group, Placebo- Controlled, Multicenter Study to Evaluate the Therapeutic Equivalence and Safety of Estradiol Vaginal Tablets 10 mcg and Vagifem® (Estradiol...

Evaluation of an Algorithm for Intensive s.c. Insulin Therapy in Emergency Room Patients With Hyperglycaemia

The aim of this study is to test the safety and efficacy of a new algorithm for intensive s.c. insulin injection in medical emergency patients with hyperglycaemia (plasma glucose concentra...

Comparison of 2 NovoFine® Needles on the Reflux of Insulin

This trial is conducted in Europe. This trial aims to ensure that there is no substantial clinically relevant difference between the two Novo Nordisk needles NovoFine® 6 x 0.30 mm and Nov...

Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects

This trial is conducted in Europe. The aim of this clinical trial is to compare the metabolism of a blood-clotting drug (recombinant Factor XIII) produced by two different manufacturers (N...

Companies [50 Associated Companies listed on BioPortfolio]

Novo A/S

Novo A/S is fully owned by the Novo Nordisk Foundation and is the holding company of the Novo Group. Novo A/S is a private limited liability company and the majority shareholder in the publicly listed...

Novo Nordisk, Inc.

Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy...

Novo Nordisk A/S

Novo A/S, the holding company of the Novo Group, is fully owned by the Novo Nordisk Foundation and was established to manage the Foundation's funds and to invest actively in other companies. What make...

Novo Nordisk

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area ...

Novo Nordisk Inc.

More Information about "Novo Nordisk, Inc." on BioPortfolio

We have published hundreds of Novo Nordisk, Inc. news stories on BioPortfolio along with dozens of Novo Nordisk, Inc. Clinical Trials and PubMed Articles about Novo Nordisk, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Novo Nordisk, Inc. Companies in our database. You can also find out about relevant Novo Nordisk, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...


Corporate Database Quicklinks



Searches Linking to this Company Record